Identification of a FGFR3-TACC3 fusion in esophageal cancer
Aberrant activation of fibroblast growth factor (FGF) signaling due to up-regulation of FGF receptor gene (FGFR) expression, alternative splicing of FGFR transcripts, FGFR mutations or translocations, or increased availability of FGF has been found to contribute to carcinogenesis [1] . FGFR fusions have recently been detected in several epithelial cancers [2, 3] , but the contribution of such fusions to cancers of the upper digestive tract, including esophageal squamous cell carcinoma (ESCC) and gastric cancer (GC), has remained largely unknown (supplementary Table S1 , available at Annals of Oncology online). We have now examined clinical specimens of ESCC (n ¼ 74, supplementary Table S2 , available at Annals of Oncology online) and GC (n ¼ 114, supplementary Table S3 , available at Annals of Oncology online) for the presence of major FGFR1, FGFR2, and FGFR3 fusion transcripts, including those with breakpoints previously uninvestigated in these cancers, with the use of a next-generation sequencing panel (see supplementary Materials and Methods and  supplementary Table S4 , available at Annals of Oncology online). We detected a targetable fusion between exon 18 of FGFR3 and exon 11 of TACC3 in one ESCC clinical specimen ( Figure 1A and B). Furthermore, split FGFR3 signals were apparent in this specimen by fluorescence in situ hybridization (FISH) with breakapart probes ( Figure 1C) . The patient was a 64-year-old man with unresectable T4bN3M1 poorly differentiated ESCC of stage IV. He was treated with palliative chemoradiotherapy including platinum-doublet followed by taxane chemotherapy. The patient died of cancer progression, with his overall survival time having been 9.5 months.
FGFR fusions with an intact kinase domain have been identified in various cancers including glioblastoma multiforme and bladder cancer, and these fusion genes were found to promote cell proliferation in vivo and in vitro [2] . FGFR aberrations have been suggested as a potential prognostic factor for ESCC, and a recurrent fusion between exon 18 of FGFR3 and exon 11 of TACC3 has also previously been detected at a frequency of 2.1% (1/48) in ESCC [4, 5] . We have now identified the same fusion at a frequency of 1.4% (1/74) in ESCC with the use of the most comprehensive panel for FGFR fusion transcript detection reported to date, whereas other FGFR fusions were not detected in the ESCC or GC specimens analyzed. Unfortunately, our results provide weak clinical evidence to support the notion.
Given that FGFR fusions are predictive of sensitivity to molecularly targeted inhibitors in several types of solid tumor, including lung adenocarcinoma, patients with ESCC harboring FGFR fusions such as FGFR3-TACC3 should be considered as potential candidates for clinical trials testing such agents. Our results provide sequence information that should prove useful for Mismatch-repair-deficient metastatic pancreatic ductal adenocarcinoma with a germline PALB2 mutation: unusual genetics, unusual clinical course A previously healthy 54-year old man was diagnosed with metastatic pancreatic ductal adenocarcinoma (PDAC) in February 2015; the primary tumor was localized in the tail of the pancreas. Histological confirmation of disease was based on a liver biopsy that showed a poorly differentiated adenocarcinoma. The patient had no family history of PDAC; however, two of his paternal aunts died of breast cancer. The patient started chemotherapy with a FOLFIRINOX regimen in March 2015 [1] , that was deescalated to mFOLFOX-6 and finally 5-FU/FA due to toxicity (thrombocytopenia, peripheral neuropathy); maintenance 5-FU/ FA was given until June 2016. During this treatment, a very good partial response occurred, with a decline in CA 19-9 levels from 8.149 U/ml (pre-treatment) to a nadir of 5 U/ml in March 2016. On sequential CT imaging studies, the liver metastases as well as the pancreatic primary decreased dramatically in size, and the radiographic finding correlated well with a rapid clinical benefit response (e.g. no further need for analgesics since May 2015).
After the first preliminary data on the role of anti-PD-1 treatment in non-colorectal gastrointestinal cancers harboring a mismatch-repair deficiency (dMMR) were presented [2] , and in the light of limited chemotherapeutic options due to persistent (treatment-associated) thrombocytopenia, we decided to determine the MMR status in our patient. At our reference laboratory for molecular pathology, a PCR-based assay found a dMMR status in the microsatellite markers BAT25, D5S536, and D17S250 of the NCI consensus set. A subsequent human genetic counseling was initiated with the addition of a gene panel diagnostic tool in order to determine germline mutations. Interestingly, this analysis found no mutations in genes associated with a HNPCC syndrome, but a novel-at least to our knowledge not previously describedheterozygous frameshift mutation (c.1725dupG; pSer576Glufs*2) in the partner and localizer of BRCA2 (PALB2) gene [3] . Furthermore, two genetic variants of unknown clinical significance in the BRCA2 gene (c.2459A > G; pAsp820Gly) and in the ATM gene (c.1066-6T > G; p.?) were detected.
Upon disease progression in July 2016, an experimental off-label treatment with the anti-PD1 inhibitor pembrolizumab was initiated [2] . Pembrolizumab was given at a dose of 200 mg every 3 weeks in analogy to the ongoing KEYNOTE-177 study in dMMR colorectal cancer (NCT02563002). Treatment was tolerated well; however, after three applications of pembrolizumab, a significant clinical (increase in abdominal pain), biochemical (increase in CA 19-9 levels from 72 to 803 U/ml) and radiographic disease progression occurred. Based on the molecular findings mentioned above, we thus decided to re-introduce a mFOLFOX-6 regimen in September 2016 as platinum-induces DNA double strand breaks are insufficiently repaired in the presence of defect PALB2 [5] .
It is well known that a subset of PDAC patients can be characterized by specific molecular alterations (e.g. BRCA mutations)
